Saturday 17 October 2026
Export BHVN’s income statement to Excel — free account
Biohaven Ltd.
BHVN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 53.1%, free cash flow grew 49.1% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
10.78
0.65
−5.69%
Follow BHVN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (799.46%) | (333.00%) | (310.75%) | (522.08%) |
+8 more TTM periods Free account |
|
| (127.41%) | (139.99%) | (138.54%) | (169.65%) | ||
ROIC |
(9,245.36%) | (1,733.01%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(235.69%) | (185.67%) | (275.31%) | (341.98%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(3.40) | (4.03) | (5.67) | (6.15) | |
Free Cash Flow |
(512.10) | (594.23) | (610.15) | (650.27) | |
Capital Expenditures |
(0.71) | — | (0.71) | (0.76) | |
| Other line items | |||||
Cash ROIC |
(94.91%) | (82.62%) | (100.01%) | (127.17%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.87 | 0.92 | 0.82 | 0.83 | |
Depreciation/Fixed assets |
0.68 | 0.66 | 0.62 | 0.56 | |
Capex/Depreciation |
(0.07) | 0.00 | (0.07) | (0.08) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.39) | (4.03) | (5.66) | (6.14) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates